Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China release_rev_db790748-e21f-4b86-9fcf-48df738aa4ed

by Yuan Jiang, Xingwei Wang

Published in European journal of hospital pharmacy. Science and practice by BMJ.

2020   ejhpharm-2020-002208

Abstract

To determine whether the first-line treatment using pembrolizumab plus standard chemotherapy of platinum and pemetrexed for patients with metastatic, non-squamous, non-small-cell lung cancer (NSCLC) is cost-effective in China. We applied partitional survival analysis to assess the cost-effectiveness of pembrolizumab plus the cytotoxic chemotherapy (cisplatin/carboplatin and pemetrexed) in metastatic NSCLC in China. We took into account direct medical costs according to the data derived from the KEYNOTE-189 trial and literature. Incremental cost-effectiveness ratio (ICER) was assessed as per life-year (LY) and per quality-adjusted life-year (QALY), with 3% per year discounted rate of costs and outcomes. In the performance of sensitivity analysis, cost of disease-management, utility-PFS (progression-free survival), utility-PD (progressive disease) and the discount were considered as variables. In scenario analysis, a philanthropic support programme in China was considered. The threshold was set to be $28 106/QALY (corresponding to three times the GDP in China). Treatment with pembrolizumab plus platinum and pemetrexed chemotherapy was estimated to increase cost by $139 168 compared with $73 081 (the cost of treatment with chemotherapy alone), leading to ICER of $80 444/LY and $96 644/QALY. Incremental costs/QALY are $90 419, $91 399 and $109 229 for programmed death ligand-1 TPS (tumour proportion scores) ≥50%, 1%-49% and <1% subgroups, respectively. Sensitivity analysis revealed that the price of pembrolizumab and the cost of disease-management in progressive-disease state were major variables. In patients with metastatic non-squamous NSCLC, pembrolizumab plus standard chemotherapy of platinum and pemetrexed as the first-line treatment is not cost-effective in China, regardless of TPS.
In text/plain format

Type  article-journal
Stage   published
Date   2020-07-31
Language   en ?
Journal Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  2047-9956
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Revision

This is a specific, static metadata record, not necessarily linked to any current entity in the catalog.

Catalog Record
Revision: db790748-e21f-4b86-9fcf-48df738aa4ed
API URL: JSON